Boston Scientific Medical Device Limited

Boston Scientific Medical Device Limited has been granted 107 US utility patents between 2022 and 2025, placing Boston Scientific Medical Device Limited at rank #3,447 across all assignees tracked by PlainPatent. This portfolio spans 22 distinct Cooperative Patent Classification (CPC) subclasses, averaging 16.8 claims per patent with primary concentration in A61B (DIAGNOSIS; SURGERY; IDENTIFICATION). As a Foreign Corporation, Boston Scientific Medical Device Limited is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 62.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Historical data spans 2022 through 2025, with 107 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Boston Scientific Medical Device Limited's 16.8 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 22 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Boston Scientific Medical Device Limited against peers pursuing similar technology classes.